Bara Abujaber

Bara Abujaber

Auto-generated profile, based on publicly available information

Bara Abujaber

MedStar Washington Hospital Center, Department of Internal Medicine, Washington, DC, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2024 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
HRHasan Rawashdeh
Hasan Rawashdeh
TATamara Alalawne
Tamara Alalawne
BABara Abujaber
Bara Abujaber
NANoura Alshraiedeh
Noura Alshraiedeh
SHShereen Hamadneh
Shereen Hamadneh

30 May 2025 in Clinical Endoscopy
Verified
Journal Article
Open access
SPSpyros Peppas
Spyros Peppas
ASAdvait Suvarnakar
Advait Suvarnakar
BABara A. Abujaber
Bara A. Abujaber
NANadera Altork
Nadera Altork
AAAmer Arman
Amer Arman
WCWon Kyoo Cho
Won Kyoo Cho
Background/Aims: Evidence suggests comparable outcomes between endoscopic ultrasound (EUS) and endoscopic retrograde cholangiopancreatography (ERCP) in the biliary drainage of malignant distal biliary obstruction (MDBO). We conducted an updated systematic review and meta-analysis comparing the EUS with ERCP in the management of MDBO.Methods: We performed a literature search using the Medline, Embase and Cochrane databases, including randomized controlled trials comparing EUS and ERCP in patients with MDBO. Meta-analysis was performed using the random-effects model using the STATA ver. 17.0 software.Results: Both procedures were comparable in technical (risk ratio [RR], 1.01; 95% confidence interval [CI], 0.78–1.30) and clinical (RR, 1.10; 95% CI, 0.85–1.41) success. No difference was identified in total adverse events (RR, 0.75; 95% CI, 0.42–1.35), acute cholangitis (RR, 0.84; 95% CI, 0.43–1.62), stent patency (RR, 1.13; 95% CI, 0.87–1.46) and mean stent patency time (mean difference, –0.01; 95% CI: –0.21 to 0.19). ERCP was associated with a higher risk of procedure-related pancreatitis (RR, 0.17; 95% CI, 0.04–0.68) and statistically non-significant higher risk for reintervention (RR, 0.61; 95% CI, 0.37–1.01).Conclusions: Although EUS and ERCP were comparable in terms of efficacy and safety, ERCP was associated with a higher risk of procedure-related pancreatitis and reintervention, with the latter finding not reaching statistical significance.

7 March 2026 in JGH Open
Verified
Journal Article
Open access
ASAhmed El Sabagh
Ahmed El Sabagh
AAAhmad Abdulraheem
Ahmad Abdulraheem
AJAriel Jimenez
Ariel Jimenez
BABara Abujaber
Bara Abujaber
UAUsman Afzal
Usman Afzal
AMAlireza Meighani
Alireza Meighani
Background: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) improve glycemic control and promote weight loss but may increase gastric residue, raising concerns during esophagogastroduodenoscopy (EGD). African American patients remain underrepresented in research on these agents. Methods: We performed a retrospective cohort study at a single tertiary referral center, including adults (≥ 18 years) undergoing elective EGD. Participants were divided into two groups based on documented GLP‐1 RA use within 7 days of EGD versus no use. Outcomes included the presence of residual gastric contents, procedure abortion due to gastric residue, procedural bleeding, and post‐procedural hospitalization. We applied multiple imputation for missing data and entropy balancing for covariate adjustment, reporting odds ratios (OR) and 95% confidence intervals (CI). Results: Among 1408 participants, 270 used GLP‐1 RAs. Compared to non‐users, GLP‐1 RA users had a higher mean body mass index (33 vs. 30 kg/m 2 ) and hemoglobin A1c (7.43% vs. 6.54%). In the adjusted analysis, GLP‐1 RA treatment was not significantly associated with increased gastric content (OR, 1.52; 95% CI, 0.58–3.99; p = 0.395) or other procedural complications. Conversely, GLP‐1 RA use was linked to lower post‐procedural hospitalization rates (OR, 0.19; 95% CI, 0.06–0.58; p = 0.004). Conclusion: In this predominantly African American cohort, recent GLP‐1 RA therapy did not significantly elevate intra‐procedural risk or necessitate procedure abortion. These findings suggest that routine discontinuation of GLP‐1 RAs prior to EGD may not be universally required, especially for patients benefiting from improved metabolic control. Larger prospective studies are warranted to inform guideline updates for diverse patient populations.

4 August 2026 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
BABara Abujaber
Bara Abujaber
AAAhmad Al-Dwairy
Ahmad Al-Dwairy
LALoai Azar
Loai Azar
TSThomas Stirrat
Thomas Stirrat
SSSamuel Speizman
Samuel Speizman
AMAlireza Meighani
Alireza Meighani
INTRODUCTION: Patients with acute gastrointestinal bleeding (GIB) who decline allogeneic blood transfusion present a major management challenge, and comparative outcome data are limited. METHODS: We conducted a multicenter retrospective propensity score-matched cohort study across 9 hospitals in the MedStar Health network in Maryland, Washington, DC, and northern Virginia from October 2014 through October 2024. We compared 131 Jehovah's Witness (JW) patients hospitalized with upper and/or lower GIB who declined blood transfusion throughout the index hospitalization with 131 matched non-JW controls. The primary outcome was 30-day all-cause mortality. Secondary outcomes included intermediate care unit admission, intensive care unit admission, vasopressor use, length of stay, and 30-day readmission for recurrent GIB. RESULTS: Thirty-day mortality did not differ significantly between groups (odds ratio 0.68, 95% confidence interval 0.30–1.47; P = 0.327). JW patients had higher odds of intermediate care admission (odds ratio 3.41, 95% confidence interval 1.46–8.95; adjusted P = 0.028), but there were no significant between-group differences in ICU admission, vasopressor use, length of stay, or 30-day readmission. Both groups reached the same median nadir hemoglobin of 6.6 g/dL. JW patients were discharged with lower hemoglobin levels and were more likely to receive bloodless medicine consultation and adjunctive anemia-directed therapy. DISCUSSION: In this matched multicenter cohort, declining allogeneic transfusion was not associated with worse short-term outcomes among patients hospitalized with acute GIB, although closer monitoring and more intensive bloodless management were often required.

30 March 2026 in Clinical Endoscopy
Verified
Journal Article
Open access
AAAhmad Abdulraheem
Ahmad Abdulraheem
BABara Abujaber
Bara Abujaber
LALindsay Ayers
Lindsay Ayers
UAUsman Afzal
Usman Afzal
DQDania Qarkash
Dania Qarkash
WCWon Kyoo Cho
Won Kyoo Cho
Background/Aims: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for diabetes and obesity. Recent studies suggest they may negatively affect bowel preparation quality before colonoscopy (CLN), leading to inadequate bowel preparation (IBP) and repeat procedures. We conducted a systematic review and meta-analysis to assess this association.Methods: PubMed, Embase and Cochrane databases, along with abstracts from Digestive Disease Week 2024 and the American College of Gastroenterology Meeting 2024, were searched. Outcomes included IBP, repeat CLNs, and the mean difference in Boston Bowel Preparation Scale (BBPS) scores between GLP-1 RA users and non-users. Adjusted odds ratios (OR), for age, sex, body mass index, and diabetes, were pooled.Results: Twelve studies including 123,858 patients (57,699 GLP-1 RA users) were analyzed. GLP-1 RA use was associated with higher IBP risk (OR, 1.55; 95% CI, 1.11–2.16); adjusted analyses confirmed this (OR, 2.35; 95% CI, 2.02–2.74). BBPS scores were lower among GLP-1 RA users (mean difference, –0.68; 95% CI, –0.77 to –0.58). No association with repeat CLNs was observed (OR, 1.5; 95% CI, 0.88–2.56).Conclusions: GLP-1 RA use is linked to inadequate bowel preparation but not repeat CLNs. Further prospective studies are warranted to further evaluate this finding.